Biophytis Files With The FDA For Authorization To Initiate SARA-31 Phase 3 Study In Sarcopenia
Portfolio Pulse from Benzinga Newsdesk
Biophytis has filed with the FDA for authorization to initiate the SARA-31 Phase 3 study in Sarcopenia. The company is awaiting approval to proceed with the clinical trial.
July 10, 2023 | 5:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biophytis' filing with the FDA for the SARA-31 Phase 3 study could potentially boost its stock if the authorization is granted.
The FDA's approval of the SARA-31 Phase 3 study would be a significant milestone for Biophytis, potentially leading to increased investor confidence and a rise in the company's stock price. However, the outcome is uncertain until the FDA's decision is announced.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100